戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 vely-followed autopsied cohort who underwent ante-mortem (11)C-Pittsburgh compound B imaging; using t
2 tensively studied in rodents but the lack of ante mortem accessibility to human brain at the cellular
3                         In the 35 cases with ante-mortem amyloid imaging, a transition between Thal a
4                                              Ante-mortem and post-mortem PET imaging at 120 h post-in
5 tween regional 11C-PK11195 binding potential ante-mortem and the burden of post-mortem CD68+ phagocyt
6 global cognitive function from participants' ante-mortem annual cognitive assessments, while sleep fr
7                                       In the ante-mortem case-control study, by contrast, plasma-gluc
8 lasma-glucose and plasma-copper levels in an ante-mortem case-control study.
9 ipid protein-1 ratio (MAG:PLP1), an index of ante-mortem cerebral perfusion, and fibrinogen levels, t
10 ks the necessary specificity for an accurate ante mortem clinical diagnosis of CBD.
11 Thal amyloid phase to Braak tangle stage and ante-mortem clinical characteristics in a large autopsy
12 series (n = 3618) was selected regardless of ante-mortem clinical diagnosis and neuropathologic co-mo
13 en brain arterial wall thickening and poorer ante mortem cognitive performance and diagnosis of incid
14 gression found an independent association of ante mortem CSF phosphorylated tau levels with postmorte
15  linear regression tested the association of ante mortem CSF tau levels with postmortem tau pathology
16                                              Ante-mortem CWD tests of pre-clinical cervids may be an
17  cases were well characterized, only limited ante-mortem data were presented.
18                                 We collected ante-mortem data, did verbal autopsies, and collected po
19  of a highly sensitive and specific test for ante-mortem detection of infected animals would be of gr
20 n-invasive, sensitive, and specific test for ante-mortem detection of infected animals.
21  as biofluid or neuroimaging biomarkers, for ante-mortem detection of LATE.
22 several different clinical syndromes, making ante-mortem diagnosis a challenge.
23    The identification of the variant enables ante-mortem diagnosis of similar cases and selective bre
24 ighlighted features which should improve the ante-mortem diagnostic accuracy of multiple system atrop
25 equently, the CXCL10 GEA shows promise as an ante-mortem diagnostic tool for the detection of M. bovi
26 gate the sensitivity and specificity, in the ante-mortem differentiation of probable DLB from other c
27                           Subjects underwent ante-mortem dopaminergic scanning and post-mortem assess
28 g temperature, meat, food components, animal ante-mortem factors and food additives are summarized.
29  autopsy-cases to confirm our findings of an ante-mortem GM and WM dissociation in the neuroimaging c
30 inopathies and may also have applications in ante-mortem imaging modalities.
31 fusion-associated vCJD infection, identified ante-mortem, is the third instance from a group of 23 kn
32 n brain tissue correlates with the degree of ante-mortem ischaemia.
33 ermediate to high probability of AD), and an ante-mortem MRI.
34   Infection with SARS-CoV-2 was confirmed on ante-mortem or post-mortem testing.
35 Examination scores evaluated 6 and <=2 years ante-mortem, P < 0.001 for both comparisons).
36                               Distinguishing ante-mortem pathology from post-mortem change has been a
37 luency, and executive functioning) to assess ante mortem performance.
38                                              Ante-mortem plasma phosphorylated-tau181 concentrations
39          However, distinguishing tauopathies ante mortem remains challenging, potentially due to diff
40 ne patients, including five patients without ante-mortem signs of motor neuron disease.
41 rons in each individual, and related this to ante-mortem sleep fragmentation.
42            Voxel-based morphometry, based on ante-mortem T1-weighted MRI, was used to identify cross-
43 f this in vitro prion amplification assay as ante-mortem TSE test for live and asymptomatic small rum
44  disease neuropathological changes with 1638 ante-mortem volumetric head MRI scans spanning 1.0-16.8
45 , while sleep fragmentation was derived from ante-mortem wrist-actigraphy recordings from a subset of